Arcutis Biotherapeutics
ARQT
ARQT
240 hedge funds and large institutions have $1.95B invested in Arcutis Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 66 increasing their positions, 81 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4.7% less ownership
Funds ownership: 110.08% → 105.38% (-4.7%)
19% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 81
Holders
240
Holding in Top 10
6
Calls
$13.1M
Puts
$4.26M
Top Buyers
| 1 | +$22.9M | |
| 2 | +$7.02M | |
| 3 | +$6.41M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.07M |
Top Sellers
| 1 | -$28.7M | |
| 2 | -$15.3M | |
| 3 | -$14.4M | |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.5M |
| 5 |
JP Morgan Chase
New York
|
-$9.35M |